3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Multiple Myeloma
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large B-Cell, Diffuse
2
Leukemia, Myeloid, Acute
2
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroblastoma
1
Melanoma
1
Lymphoma, T-Cell
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Lymphoma
1
Leukemia, Lymphoid
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Gliosarcoma
1
Glioblastoma
1
Central Nervous System Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Burkitt Lymphoma
1
Brain Neoplasms
1
Interventions
Temozolomide
53
Bevacizumab
45
Radiotherapy
28
Radiosurgery
21
Carboplatin
14
Erlotinib Hydrochloride
11
Radiation
10
pembrolizumab
9
Magnetic Resonance Spectroscopy
9
Etoposide
9
Vorinostat
8
Trastuzumab
8
Irinotecan
8
Sunitinib
7
Sorafenib
7
Radiotherapy, Intensity-Modulated
7
Lomustine
7
Lapatinib
7
Capecitabine
7
dabrafenib
6
Ipilimumab
6
Imatinib Mesylate
6
Cyclophosphamide
6
Sirolimus
5
Hydroxyurea
5
Everolimus
5
Bortezomib
5
temsirolimus
4
cabozantinib
4
binimetinib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Brain Neoplasms
×
Immunotherapy, Adoptive
×
Clear all
NCT02100891
2025-03-19
STIR
Medical College of Wisconsin
Phase 2
Terminated
15 enrolled
11 charts